Zoledronic acid in the management of metastatic bone disease
about
Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massZoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.Risk stratification in the hormonal treatment of patients with prostate cancerBasal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.Physician preferences for bone metastasis drug therapy in Canada.The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancerUsefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyThe Usefulness of Bone Biomarkers for Monitoring Treatment Disease: A Comparative Study in Osteolytic and Osteosclerotic Bone Metastasis Models.Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.A modified method for reducing renal injury in zoledronic Acid treatment of hypercalcemia and adverse skeletal eventsSecreted gelsolin desensitizes and induces apoptosis of infiltrated lymphocytes in prostate cancer.Amorphous, Smart, and Bioinspired Polyphosphate Nano/Microparticles: A Biomaterial for Regeneration and Repair of Osteo-Articular Impairments In-Situ.Drug Repositioning for Effective Prostate Cancer Treatment.Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom.
P2860
Q28540022-0A9E2E9D-8A7F-4DC5-BC90-2F03270EEFAAQ34389524-11818718-3CF6-4458-B5BB-A5BA68BCAC7AQ34617885-A0BEE36F-9EDE-4793-BC70-BD623288888CQ35076189-76EE6510-AC92-4EC9-B3D9-A12B7C9C1F30Q35832193-47548C19-78FF-4E07-BDB5-16990060C163Q36169862-D5450C20-C3C7-4450-A0A7-95957EA159E9Q36190094-05B80955-6961-400C-8942-AA492353646CQ36959180-D4DE2493-0464-42AA-A233-F6FFE8EF2887Q37648939-BA0A0DD2-A81A-42E0-B7AF-AAD7D9BDFB06Q37688626-7F76AF3B-9A49-4356-8544-226ADB56B134Q38381733-F0AEE463-8026-417C-BE84-EBA484144381Q42152498-ED5E5F1D-FA78-4A94-B927-575CA1AF7BB0Q46109803-6BE826C6-D865-4A64-8134-3E2AB81EB180Q48133926-38A31A95-E842-4EDA-9C0F-22AC64470F52Q55254671-5DEEBFBE-AFF3-49A7-B90F-388D8537E981Q55518625-703E1085-CA06-4BCE-A016-BE58CFB90FA2
P2860
Zoledronic acid in the management of metastatic bone disease
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Zoledronic acid in the management of metastatic bone disease
@en
type
label
Zoledronic acid in the management of metastatic bone disease
@en
prefLabel
Zoledronic acid in the management of metastatic bone disease
@en
P2860
P356
P1476
Zoledronic acid in the management of metastatic bone disease
@en
P2093
Thomas J Polascik
Vladimir Mouraviev
P2860
P304
P356
10.2147/TCRM.S2707
P577
2008-02-01T00:00:00Z